Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tmtrx Inc. is engaged in the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action is assigned to 1 distinct examiner. Such a profile indicates a singular, focused point of prosecution for the company's current patent activities, which can simplify communication but increases the impact of a single examiner's decision on the overall portfolio.
The busiest examiner for Tmtrx Inc. is HUTTER, GILLIAN A. Since the portfolio only contains a pending office action, this examiner manages the entirety of the company's active workload. The concentration within a distinct art unit and under a single examiner means that the company's immediate success in this technology area depends on a single line of communication. This focused approach requires a precise and well-supported prosecution strategy to ensure a favorable outcome from the lone examiner involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 1 | 54.5% | +46.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18741475 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | HUTTER, GILLIAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18741475 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | HUTTER, GILLIAN A | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18741475 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | HUTTER, GILLIAN A | 1625 | §103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTmtrx Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Gillian A Hutter has the most, with 1 of Tmtrx Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
